Clinical trial · Observational
Pharmacokinetics of Oral Antiplatelet Agents After Distal Gastrectomy
Impact of Radial Distal Gastrectomy for Gastric Cancer on the Pharmacokinetics of Oral Antiplatelet Agents
NCT05543863CI-TRIAL-00060937unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is aimed to investigate the changes in pharmacokinetics and efficacy of antiplatelet agents before and after distal gastrectomy in gastric cancer patients taking oral antiplatelet agents for primary or secondary treatment for cardiovascular disease and to evaluate its impact on the occurrence of postoperative bleeding complications and thromboembolic events.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Cerebrovascular Disease | — | UNRESOLVED | — |
| Stomach Neoplasm | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Platelet function testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- platelet function testing at 5 days
- timeFrame
- 5 days
- description
- Difference in the platelet function testing results between before and 5 days after surgery.
Secondary outcomes (2)
- measure
- Platelet function testing at 3 months
- timeFrame
- 3 months
- description
- Difference in the platelet function testing results between before and 3 months after surgery
- measure
- postoperative complications
- timeFrame
- 3 months
- description
- ■ incidence of postoperative bleeding and thromboembolic events within 3 months after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with pathologically proven gastric cancer of clinical stage I according to the AJCC 8th edition. * Patients who are scheduled to undergo distal gastrectomy (access: either minimally invasive surgery or open surgery) * Patients taking aspirin and/or clopidogrel for primary or secondary prevention for cardiovascular disease or cerebrovascular disease before surgery. * age 18 - 90 years * A person who voluntarily agrees to participate in this study and signs the consent form. Exclusion Criteria: * Patients with coagulation disorder or abnormal findings in coagulation test (low platelet count, prolonged PT/aPTT) * Patients taking other anticoagulants in combination * Patients with imparied liver or renal function that may affect drug metabolism. Impaired liver function: liver cirrhosis Impaired renal function: CKD grade 3 or higher * Patients requiring adjuvant chemotherapy after surgery that may affect postoperative bone marrow function and hematopoietic function (those with gastric cancer of clinical stage II or more according to the AJCC 8th edition) * Patients participating in other clinical trials within 6 months * Vulnerable patients (pregnant women, those with cognitive impairment, etc)
References
Publications (0)
Data not yet available
No reference posted for this study.